Singapore’s roll-out of Moderna Spikevax bivalent Covid-19 vaccine brought forward to Oct 14
This is because preparations for the vaccine's introduction were completed ahead of time, according to the Ministry of Health.
Hong Kong government renews call for vigilance as new variants detected
The government had earlier announced the relaxation of social distancing measures, including increasing the maximum number of persons for banquets from 120 to 240.
South Korea starts bivalent Covid-19 boosters, amid ‘twindemic’ woes
Over the past two years, South Korea was able to largely escape the spread of seasonal influenza mainly due to strict social distancing rules and mask mandates.
Indonesian Home Ministry maintains current Covid-19 restrictions until November
The Home Affairs Ministry decided to keep the restrictions after considering "the level of community transmission" as well as the "socioeconomic condition" of the population.
Cambodia striving for post-Covid growth: Hun Sen
“Going forward, against the backdrop of heightened complexities and uncertainty, the Royal Government will prioritise building resilience in the national economy,” the premier…
All Covid restrictions for inbound travellers to Cambodia lifted
Travellers will still be required to have their temperatures taken when arriving at border crossings.
Covid-19 pandemic will soon be declared over: Jokowi
However, he warned that the improvement in the Covid-19 situation would not automatically translate into better economic conditions.
South Korea’s 1st homegrown Covid-19 vaccine maker underlines global partnership
Seoul-based International Vaccine Institute, SK Bioscience, helped conduct the vaccine’s clinical trials across six countries, including Thailand and New Zealand.
Japan prepares for flu-Covid double whammy
In the two previous winters, there were no outbreaks of seasonal flu due to thorough infection prevention measures amid the novel coronavirus pandemic.
Indonesia’s BPOM approves first homegrown Covid-19 vaccine
IndoVac showed an efficacy rate of 92 per cent, with "generally mild" reported side effects and no reports of deaths linked to it in trials.